Group Leader/s
Head of lab
intro
Our research group seeks to delve into the cellular and molecular bases of pulmonary vascular dysfunction, the gateway to the body for a multitude of agents capable of compromising people's health. Our research places a special focus on understanding endothelial damage and its connection with vascular smooth muscle and the immune system, all of which are very present in the development of cardiovascular diseases. We go from rare or infrequent diseases such as pulmonary arterial hypertension to other cardiopulmonary disorders resulting from exposure to various environmental factors, such as hypoxia, certain pollutants, drugs or respiratory infections. All these cardiopulmonary diseases affect both the lung vasculature and the heart in one way or another. The ultimate goal of our research is to find new targets, biomarkers and therapeutic strategies that contribute, from basic biology and experimental pharmacology, to solving the health challenges of our society.
Members
| Eduardo Rial Zueco |
| Eduardo Oliver Perez |
| Ana Isabel Manzano Perez |
| Yolanda Sierra Palomares |
| Claudia Rallo |
| Lola Navarro Linares |
| Bertha Garcia Leon |
| Laura de la Bastida Casero |
| Nerea Sarmiento Tevar |
| Ainhoa Palacios Mejorada |
| Lucia Vazquez Gomez |
Selected Publications
*de la Bastida-Casero, L.; *García-León, B.; Tura-Ceide, O.; ºOliver, E. (*equally contributed) (ºcorresponding author) [2024]. The Relevance of the Endothelium in Cardiopulmonary Disorders. Int J Mol Sci, 25(7): 9260
Fernández-Tocino, M., Pun-Garcia, A., Gómez, M., Clemente-Moragón, A., Oliver, E., Villena-Gutierrez, R., Trigo-Anca, S., Díaz-Guerra, A., Sanz-Rosa, D., Prados, B., Del Campo, L., Andrés, V., Fuster, V., de la Pompa, J. L., Cádiz, L., & Ibañez, B. [2024]. β3-Adrenergic receptor overexpression in cardiomyocytes preconditions mitochondria to withstand ischemia–reperfusion injury. Basic Res Cardiol, 1-12
Díaz-Guerra, A., Villena-Gutiérrez, R., Clemente-Moragón, A., Gómez, M., Oliver, E., Fernández-Tocino, M., Galán-Arriola, C., Cádiz, L., & Ibáñez, B. [2024]. Anthracycline Cardiotoxicity Induces Progressive Changes in Myocardial Metabolism and Mitochondrial Quality Control: Novel Therapeutic Target. J Am Coll Cardiol CardioOnc, 6 (2) 217–232
Santamans,A.M., Cicuendez, B., Mora, A., Villalba-Orero, M., Rajlic, S., Crespo, M., Vo, P., Jerome, M., Macias, A., Lopez, J.A., Leiva, M., Rocha, S.F., Leon, M., Rodriguez, E., Leiva, L., Pinto-Chocano, A., Garcia-Lunar, I., Garcia-Alvarez, A., Hernansanz-Agustin, P., Peinado, V.I., Barrera, J.A., Ibanez, B., Vazquez, J., Spinelli, J.B., Daiber, A., Oliver, E., Sabio, G. [2024]. MCJ: A mitochondrial target for cardiac intervention in pulmonary hypertension. Sciences Advances, 10, eadk6524.
Pun-García, A., Clemente-Moragón, A., Villena-Gutierrez, R., Gómez, M., Sanz-Rosa, D., Díaz-Guerra, A., Prados, B., Medina, J. P., Montó, F., Ivorra, M. D., Márquez-López, C., Cannavo, A., Bernal, J. A., Koch, W. J., Fuster, V., de la Pompa, J. L., Oliver, E., & Ibanez, B. [2022]. Beta-3 adrenergic receptor overexpression reverses aortic stenosis–induced heart failure and restores balanced mitochondrial dynamics. Basic research in cardiology, 117(1), 62.
*Clemente-Moragón, A., *Oliver, E., Calle, D., Cussó, L., Tech, M. G., Pradillo, J. M., Castejón, R., Rallón, N., Benito, J. M., Fernández-Ferro, J. C., Carneado-Ruíz, J., Moro, M. A., Sánchez-González, J., Fuster, V., Cortés-Canteli, M., Desco, M., & Ibáñez, B. (*equally contributed) [2023]. Neutrophil β1 adrenergic receptor blockade blunts stroke-associated neuroinflammation. British journal of pharmacology, 180:459–478
*Clemente-Moragón, A., *Martínez-Milla, J., Oliver, E., Santos, A., Flandes, J., Fernández, I., Rodríguez-González, L., Serrano Del Castillo, C., Ioan, A. M., López-Álvarez, M., Gómez-Talavera, S., Galán-Arriola, C., Fuster, V., Pérez-Calvo, C., & Ibáñez, B. (*equally contributed) [2021]. Metoprolol in Critically Ill Patients With COVID-19. Journal of the American College of Cardiology, 78(10), 1001–1011.
Clemente-Moragón, A., Gómez, M., Villena-Gutiérrez, R., Lalama, D. V., García-Prieto, J., Martínez, F., Sánchez-Cabo, F., Fuster, V., *Oliver, E., & *Ibáñez, B. (*co-corresponding authors) [2020]. Metoprolol exerts a non-class effect against ischaemia-reperfusion injury by abrogating exacerbated inflammation. European heart journal, 41(46), 4425–4440.
Spaczyńska, M., Rocha, S. F., & *Oliver, E. (*corresponding author) [2020]. Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies. ACS pharmacology & translational science, 3(4), 598–612.
Nuche, J., Segura de la Cal, T., Jiménez López Guarch, C., López-Medrano, F., Delgado, C. P., Ynsaurriaga, F. A., Delgado, J. F., Ibáñez, B., *Oliver, E., & *Subías, P. E. (*co-corresponding authors). [2020]. Effect of Coronavirus Disease 2019 in Pulmonary Circulation. The Particular Scenario of Precapillary Pulmonary Hypertension. Diagnostics (Basel, Switzerland), 10(8), 548.
*Oliver, E., Mayor, F., Jr, & D'Ocon, P. (*corresponding author). [2019]. Beta-blockers: Historical Perspective and Mechanisms of Action. Revista espanola de cardiologia (English ed.), 72(10), 853–862.
*Zhao, L., *Oliver, E., Maratou, K., Atanur, S. S., Dubois, O. D., Cotroneo, E., Chen, C. N., Wang, L., Arce, C., Chabosseau, P. L., Ponsa-Cobas, J., Frid, M. G., Moyon, B., Webster, Z., Aldashev, A., Ferrer, J., Rutter, G. A., Stenmark, K. R., Aitman, T. J., & Wilkins, M. R. (*co-first authors). [2015]. The zinc transporter ZIP12 regulates the pulmonary vascular response to chronic hypoxia. Nature, 524(7565), 356–360.
Funding
Funded by Ministerio de Ciencia e Innovación / Agencia Estatal de Investigación (PID2021-123167OB-I00, CEX2021-001226-S-20-8, PRE2022-104403 and RED2022-134299-T); by CSIC (Talent Attraction program 20222AT010 and Intramural 202420E038), by Comunidad de Madrid (PIPF-2022/SAL-GL-24824), by La Marató de TV3 Foundation (202336-30-31) and by CIBER-ISCIII (CV24PI04/2024).
 |
 |
 |
|
|
More info
Patents
Oliver E, Zhao L, Wilkins MR, and Aitman T. PCT/GB2016/052297. ZIP12 as a Therapeutic/Screening Candidate for Hypoxia-Induced Pulmonary Hypertension WO/2017/017446. Priority: UK (extended to world-wide application), Date: 28/07/2015. Status: entered into national phases in EP and US. Holder: Imperial Innovations Ltd.
Sánchez‐Sancho, F.; Csáky, A. G.; del Pozo, C; del Pozo, J.; Marcilla, A.; Ibáñez Cabeza, B.; Oliver, E. Cumella, J. M.; Roscales, S. P202330530, N/Ref.: 2022_82 ES. Imidazo[1,2-a]pyridine derivatives with anti-inflammatory activity. P202330530. Priority: España. Fecha: 27/06/2023. Status: Solicitada. Holders: Universitat de València, Consejo Superior de Investigaciones Científicas, Universidad Complutense de Madrid, Centro Nacional de Investigaciones Cardiovasculares Carlos III.
Honors and Awards
- Tenured Scientist. 2024-
- I3 Certificate. 2023
- Ramón y Cajal Fellow. Agencia Estatal de Investigación (RYC2020-028884-I) 2022-2024
- ‘Prismas’ Honorific mention to the singular project modality for the initiative #CienciaenelParlamento. Museos Científicos Coruñeses. 2019
- SRUK Mentoring recognition award. SRUK/CERU. 2018
- Talent Atraction Senior Fellow (mod.1). Comunidad Autónoma de Madrid. 2018-2022
- 1st Prize in Biological and Biomedical Sciences for Tutors. 16th ARQUIMEDES University Contest. Ministry of Education, Culture and Sports. 2017
- Winner of the 32nd SEF Young Investigator Award to best career under 35 years old. Spanish Society of Pharmacology (SEF). 2017
- Winner of the EPHAR Young Investigator Award. The Federation of European Pharmacological Societies (EPHAR). 2016
- International Postdoctoral CNIC Fellow. Marie Sklodowska-Curie COFUND. 2016-2018
- Expert on expatriate scientific networks. 'Los 100 de Cotec', Fundacion Cotec. 2016-2023
- FPU Phd Fellow. Ministry of Science and Education. 2005-2009
RECENT NEWS about the group, click here.
*We are looking for candidates to do a Master and/or PhD with us! If you are interested in joining our group, send an e-mail to Eduardo including your CV and a motivation letter.
We are part of:
 |
 |
 |
 |
|